<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401709</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01-101</org_study_id>
    <nct_id>NCT04401709</nct_id>
  </id_info>
  <brief_title>Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer</brief_title>
  <official_title>A Randomized, Multi-center Phase III Trial of Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine Alone in Curatively Resected Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is an open-label, multicenter, phase 3 clinical trial to study the&#xD;
      efficacy and safety of adjuvant gemcitabine + capecitabine combination treatment in patients&#xD;
      with resectable biliary tract cancer according to imaging studies after surgery. All the&#xD;
      patients must complete a consent forms before participating in the clinical trial, and the&#xD;
      estimated enrollment period is 36 months after IRB approval.&#xD;
&#xD;
      Drug Dose and Schedule:&#xD;
&#xD;
        -  Cohort 1: Gemcitabine/Capecitabine, every 4 weeks, total 6 cycles gemcitabine1,000 mg/m2&#xD;
           over 30 min D1, D8, D15 capecitabine 1660 mg/m2, D1-21&#xD;
&#xD;
        -  Cohort 2: Capecitabine, everu 3 weeks, total 8 cycles capecitabine 2,500 mg/m2 D1-14&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study Background &amp; Rationale:adjuvant capecitabine monotherapy following surgery is&#xD;
           regarded as standard treatment after phase 3 BILCAP trial, we need further phase 3&#xD;
           clinical trials to evaluate efficacy of doublet combination adjuvant chemotherapy for&#xD;
           Biliary Track Cancer after surgery. Since Korea has much higher incidence rate of&#xD;
           Biliary Track Cancer compared to western countries, Korea is considered to be a region&#xD;
           that can lead large-scale Biliary Track Cancer clinical trials. In this background, we&#xD;
           intend to conduct a randomized phase 3 study to compare adjuvant gemcitabine+cisplatin&#xD;
           combination therapy with camecitabine monotherapy following curative intent surgical&#xD;
           resection in patients with Biliary Track Cancer .&#xD;
&#xD;
        2. Primary Objective:&#xD;
&#xD;
             -  Disease-free survival at 24 months (2-year DFS)&#xD;
&#xD;
        3. Primary Hypothesis:&#xD;
&#xD;
           Adjuvant gemcitabine and capecitabine combination treatment confers diseae free survival&#xD;
           benefit over capecitabine monotherapy after curative intent surgical resection of&#xD;
           biliary tract cancer&#xD;
&#xD;
        4. Study Design:&#xD;
&#xD;
      This clinical trial is an open-label, multicenter, phase 3 clinical trial to study the&#xD;
      efficacy and safety of adjuvant gemcitabine + capecitabine combination treatment in patients&#xD;
      with resectable biliary tract cancer according to imaging studies after surgery. All the&#xD;
      patients must complete a consent forms before participating in the clinical trial, and the&#xD;
      estimated enrollment period is 36 months after IRB approval.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two-year disease free survival (DFS)</measure>
    <time_frame>24 months later</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months later</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">490</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine/Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemcitabine1,000 mg/m2 over 30 min D1, D8, D15 capecitabine 1660 mg/m2, D1-21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capecitabine 2,500 mg/m2 D1-14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine/Capecitabine</intervention_name>
    <description>gemcitabine 1,000 mg / m2 IV on day 1, 8, and 15 of each cycle Capecitabine 1,660mg / m2 PO twice daily 1 ~ 21 days for 4 weeks</description>
    <arm_group_label>Gemcitabine/Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 ~ 14 days for 3 weeks</description>
    <arm_group_label>Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed adenocarcinoma of biliary tract canacer&#xD;
             (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder&#xD;
             cancer) after curative intent R0 or R1 surgical resection&#xD;
&#xD;
          2. Pathologic disease stage of T2-4, N0-2, M0 after surgery, according to AJCC 8th TNM&#xD;
             staging&#xD;
&#xD;
          3. Patients who complete resection (R0 or R1 resection) for biliary tract cancer within&#xD;
             12 weeks of the adjuvant chemotherapy&#xD;
&#xD;
          4. No distant metastasis&#xD;
&#xD;
          5. ECOG performance sstatus score of 0 or 1&#xD;
&#xD;
          6. Age 19 years or older&#xD;
&#xD;
          7. Adequate bone marrow fuction (neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L and&#xD;
             hemoglobin ≥9 g/dL)&#xD;
&#xD;
          8. Adequate liver function (total bilirubin &lt; 1.5 fold the upper limit of normal of the&#xD;
             study site (ULN), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &lt;&#xD;
             5.0 x ULN)&#xD;
&#xD;
          9. Adequate kidney function (Creatinine &lt; 1.5 x ULN)&#xD;
&#xD;
         10. Unresolved systemic active infection (except for chronic viral hepatitis taking&#xD;
             antiviral drugs)&#xD;
&#xD;
         11. Not receiving other drugs for clinical trials or chemotherapy within 30 days prior to&#xD;
             randomization&#xD;
&#xD;
         12. A female participant who is not post-menopausal or amenorrhea less than 12 consecutive&#xD;
             months without specific reasons is eligible to participate if she is not pregnant,&#xD;
             confirmed by serum tests within 7 days before the initiation of chemotherapy&#xD;
&#xD;
         13. The participants provide written informed consent for the study.&#xD;
&#xD;
         14. No prior chemotherapy for biliary tract cancer&#xD;
&#xD;
         15. Participants of childbearing potential must agree to use an adequate method of&#xD;
             contraception for the course of the study throught 120 days after the last dose of&#xD;
             chemotherapy (oral contraceptives or mechanical contraception such as intrauterine&#xD;
             devices or contraceptive barriers and etc). Childbearing potential female is who is&#xD;
             not post-menopausal or amenorrhea less than 12 consecutive months without specific&#xD;
             reasons&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other histology type than adenocarcinoma (such as HCC-CCC mixed type or neuroendocrine&#xD;
             tumor)&#xD;
&#xD;
          2. Ampula of vater cancer&#xD;
&#xD;
          3. Has known additional malignancy (participants with non-melanoma skin cancer, or&#xD;
             carcinoma in situ (e.g. breast carcinoma, prostate cancer) that have undergone&#xD;
             potentially curative therapy without recurrence for more than 3 years are not&#xD;
             excluded)&#xD;
&#xD;
          4. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the study, interfere with the subject's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
          5. Has an active infection requiring systemic therapy (bacteria, virus, fungal, etc)&#xD;
&#xD;
          6. Has a known history of Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
          7. Has an active of hepatitis A or B (patients under anti-B-viral treatment with HBV DNA&#xD;
             1000≤copies/ml is allowed to particiapte).&#xD;
&#xD;
          8. Has a history of severe hemorrhage (gastrointestinal or neurologic) within 2 weeks&#xD;
             prior randomization&#xD;
&#xD;
          9. Is unable to take oral drug due to gastrointestinal obstruction or any other&#xD;
             conditions.&#xD;
&#xD;
         10. Any history of significant cardiac disease within 3 months prior to randomization&#xD;
             including unstable angina, NYHA (The New York Heart Association )III or IV congestive&#xD;
             heart failure, myocardiac infarction, or severe uncontrolled arrhythmias&#xD;
&#xD;
         11. Pregnant, breast-feeding or pregnancy test positive female patients&#xD;
&#xD;
         12. Has any contraindications for investigational drug&#xD;
&#xD;
               -  History of hypersensitivity to capecitabine or gemcitabine&#xD;
&#xD;
               -  Any hypersensitivity to fluorouracil drugs&#xD;
&#xD;
               -  Concurrent administration with sorivudine or brivudine&#xD;
&#xD;
               -  DPD(dihydro-pyridine dehydrogenase) deficiency&#xD;
&#xD;
               -  History of TS-1(tegafur / gimeracil / oteracil) administration&#xD;
&#xD;
               -  Galactose intolerance, Lapp lactase deficince, glucose-galactose malabsorption&#xD;
&#xD;
               -  Interstitial pneumonia or pulmonary fibrosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JoonOh Park, doctor</last_name>
    <phone>82-2-3410-3459</phone>
    <email>joonoh.park@samsung.com</email>
  </overall_contact>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Joon Oh Park</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

